中国第二款，即科兴疫苗，土耳其第三期83.5%。10 weeks 内可生产出针对变异病毒的产品。2021.6.1 WHO批准

[lindamy]

（法新社）消息.
巴基斯坦总统阿尔维本月15日接种中国国药疫苗Sinopharm.在週一（29日），阿尔维在推特中公布确诊消息，指出他在接种首剂中国新冠疫苗后仍验出病毒阳性反应。除了总统阿尔维以外，巴基斯坦总理伊姆兰汗（Imran Khan）本月在注射过第1剂疫苗后，在3月20日也验出病毒阳性反应，目前正在私人住宅中隔离.伊姆兰汗的妻子以及执政党「巴基斯坦正义运动党」的两名高层也确诊阳性。
在週一（29日），阿尔维在推特中公布确诊消息，指出他在接种首剂中国新冠疫苗后仍验出病毒阳性反应。除了总统阿尔维以外，巴基斯坦总理伊姆兰汗（Imran Khan）本月在注射过第1剂疫苗后，在3月20日也验出病毒阳性反应，目前正在私人住宅中隔离.伊姆兰汗的妻子以及执政党「巴基斯坦正义运动党」的两名高层也确诊阳性。

据2月份的报道，以色列辉瑞疫苗60万人，打了两针以后两周测（此时抗体最高），608人感染，占0.1%，21人住院，其中7人重症，都有基础病，3人中度，11人轻症。

4:08 p.m. ET, February 17, 2021

Pfizer vaccine is about 95% effective against Covid-19, Israeli data shows​

From CNN's Amir Tal and Elizabeth Cohen

A health worker fills a syringe with the Pfizer-BioNTech Covid-19 vaccine. Christof Stache/AFP/Getty Images

Data from more than 600,000 vaccinated Israelis shows the Pfizer vaccine is 95% effective, with only 21 vaccinated people ending up in the hospital with Covid-19, according to a press release from Maccabi Healthcare Services, Israel’s second largest healthcare provider.

The findings, while preliminary, suggest the vaccine remains remarkably effective in the real world and not just in the clinical trials conducted last year by Pfizer and BioNTech.

Maccabi looked at data from about 602,000 of its members who were at least one week past their second dose of the vaccine. Among them, 7 were hospitalized with severe symptoms, 3 with moderate symptoms, and 11 with mild symptoms.

All of the hospitalized members were over age 50, and half of them had a chronic health condition, such as morbid obesity, according to Ido Hadari, a Maccabi spokesman.

Among the 602,000 vaccinated members, tests showed that 608 became infected with Covid-19. Maccabi did not routinely test members, but of the 608, 35% chose to get tested because they had symptoms of Covid-19 and 65% chose to get tested because they had been exposed to someone with the virus.
Maccabi compared that infection rate with a group of 528,000 members who had not yet received the vaccine. In this control group, 20,621 people, or nearly 4%, were identified as having Covid-19.

Maccabi’s findings are similar to data released earlier this week by Israel’s largest healthcare provider, which found the vaccine was 94% effective. Pfizer’s clinical trial showed about the same efficacy.

Pfizer vaccine is about 95% effective against Covid-19, Israeli data shows

 

[草头将军]

（法新社）消息.
巴基斯坦总统阿尔维本月15日接种中国国药疫苗Sinopharm.在週一（29日），阿尔维在推特中公布确诊消息，指出他在接种首剂中国新冠疫苗后仍验出病毒阳性反应。除了总统阿尔维以外，巴基斯坦总理伊姆兰汗（Imran Khan）本月在注射过第1剂疫苗后，在3月20日也验出病毒阳性反应，目前正在私人住宅中隔离.伊姆兰汗的妻子以及执政党「巴基斯坦正义运动党」的两名高层也确诊阳性。
在週一（29日），阿尔维在推特中公布确诊消息，指出他在接种首剂中国新冠疫苗后仍验出病毒阳性反应。除了总统阿尔维以外，巴基斯坦总理伊姆兰汗（Imran Khan）本月在注射过第1剂疫苗后，在3月20日也验出病毒阳性反应，目前正在私人住宅中隔离.伊姆兰汗的妻子以及执政党「巴基斯坦正义运动党」的两名高层也确诊阳性。

中国疫苗防止感染的有效率不是100%。

巴总统 15 号接种，29 号检测，刚两周第二针都还没打，能说明什么问题？
巴总理 18 号接种，19 号检测阳性，为啥不把日期放上去？别有用心
转这种贴，脑子坏掉了？

 

[向问天]

 

[向问天]

印尼要增加购买1亿剂科兴疫苗。

Redirect Notice

 

[向问天]

智利卫生部的官方数据解读。
对付变异病毒，科兴疫苗更有效。

 

[向问天]

智利卫生部的官方数据解读。
对付变异病毒，科兴疫苗更有效。

我的预测。

多打一针总比再去开发一款新的mRNA疫苗省时间。再说病毒变异越来越快，mRNA疫苗开发再快也追不上。而灭活疫苗，以不变应万变，必须是最后赢家。

 

[向问天]

Turkish doctors agree that they now have enough data in the field to review the efficacy of CoronaVac more precisely.

"Based on our field observations, we can say that the Sinovac vaccine prevents deaths and intensive care hospitalization 100 percent," Nurettin Yiyit, chief physician of the hospital, told Xinhua, referring to the general situation in the country.

"The phase studies had already proved its efficacy, but our field notes are even better," he continued while inspecting the ongoing vaccinations.

Turkish physicians hail high efficacy of China's Sinovac vaccine

newsaf.cgtn.com

 

[向问天]

科兴说能在 10 weeks 内生产出针对变异病毒的疫苗​

Sinovac can produce updated COVID-19 vaccines against variants in 10 weeks
By
Wang Qi
Published: May 12, 2021 10:18 PM

Sinovac COVID-19 vaccine. Photo: VCG

Amid global concerns over the variant found in India that appears to be of high infectiousness and transmissibility, Chinese experts said Chinese vaccine manufacturers will be able to produce suitable vaccines against the variant in about two months.

The comment came as Chinese manufacturer Sinovac, whose COVID-19 vaccine is being used in more than 30 countries, disclosed to Ta Kung Pao newspaper that the company is studying different mutations and an updated vaccine suitable for these mutations could be produced in 10 weeks at the quickest after the company cultivates the mutated strain successfully.

Liu Peicheng, the spokesperson of Sinovac, told media on Tuesday in a Beijing-based manufacturing factory that the company is researching the different mutations of the novel coronavirus, a vital step before updated vaccines come into production.

With a mature vaccine pipeline in place, future production of COVID-19 vaccine will be much faster, Liu said, noting that Sinovac has been using its vaccine on a large scale in Brazil, Chile and in areas where it has found mutated strains, and has seen good protection against the virus.

Experts reached by Global Times said that Sinovac's claimed speed is not an exaggeration. After getting the mutant strain, manufacturers only need to replace the seed virus in the fermenter, without making any adjustment in other procedures.

The upgrade can be finished in two months, with an animal trial or a phase I human trial, and that's enough for emergency use, Tao Lina, a Shanghai-based vaccine expert, told the Global Times on Wednesday.

The original version of inactivated vaccine may offer slightly less protection against the virus with mutant strains, but a third dose of updated vaccine on top of the previous shots will provide much greater protection, Tao said.

Chinese experts said that insufficient evidence has been found to show that the B.1.617 variant found in India and classified by the WHO as "a variant of concern" could make current vaccines less effective. Experts noted that as the epidemic in India is still unstable and the mutation could continue to mutate, it is not a proper time to select and cultivate the strain for vaccines.

Yang Zhanqiu, deputy director of the pathogen biology department at Wuhan University, told the Global Times on Wednesday that deciding a strain of virus to produce an inactivated vaccine is a complex process, which usually is conducted at the end of an epidemic, to select the strain with the greatest impact.

But experts tried to ease public concern, saying that current vaccines are still able to provide protection against most mutations despite some reduction in efficacy. Vaccine research and development is still getting ahead of the virus mutation, they said.

They said that Sinovac's updated vaccine may elevate their status in the highly competitive international vaccine market with mRNA vaccines dominating the West as they can update the vaccines quicker due to mature technology, while more tests and research are needed to update mRNA vaccines as the technology has rarely been applied in the real world before the COVID-19 pandemic.

 

[lindamy]

Indonesia Says Sinovac's Vaccine 98% Effective to Prevent Deaths From Covid-19
Indonesia Says Sinovac's Vaccine 98% Effective to Prevent Deaths From Covid-19

Jakarta. Coronavac, a vaccine made by Chinese pharmaceutical company Sinovac has been 98 percent effective in reducing the number of deaths due to Covid-19 among health workers in Jakarta, according to a study released by the Health Ministry on Wednesday.

………………

The study evaluated Covid-19 data between Jan 13 — when the vaccination first started in Indonesia — and March 18, tracking 128,290 health workers who had not suffered from the disease before the study period.

The study found only one Covid-19 related death among 91,777 health workers in 28 to 63 days after receiving two doses of Sinovac's vaccine. That was equal to a case fatality rate (CFR) of 0.0001 percent.

In comparison, there were three deaths among 8,485 health workers who received only one dose of the vaccine, resulting in the group's CFR of 0.03 percent. Among 28,055 health workers who had yet to be vaccinated, the study found 17 deaths, resulting in a 0.66 percent death rate.

In other words, the death rate dropped from 66 in 10,000 people to just one after two doses of vaccination, a decline of 98 percent — a number epidemiologists refer to as the vaccine effectiveness.

The number of Covid-19 deaths among health workers in the study

Groups	Deaths	Total	%
Not vaccinated	17	28,055	0.66
Vaccinated with the first dose	3	8,458	0.03
Vaccinated with the second dose	1	91,777	0.001

……………

Also, the study found that complete Coronavac vaccination would be able to reduce hospitalization by 96 percent.

The number of Covid-19 hospitalization among health workers in the study

Groups	Hospitalization	Total	%
Not vaccinated	102	28,055	0.36
Vaccinated with the first dose	24	8,458	0.20
Vaccinated with the second dose	7	91,777	0.007

Source: Health Ministry

…………

The number of Covid-19 infection among health workers in the study

Groups	Infected	Total	%
Not vaccinated	2,431	28,055	8.66
Vaccinated with the first dose	657	8,458	7.76
Vaccinated with the second dose	521	91,777	0.56

Source: Health Ministry
…………………

Indonesia has administered 22.5 million vaccines to 13.7 million people in priority groups, including the health workers, workers in private and public service industries, and the elderly since the vaccination began on Jan 13, the ministry data showed on Thursday.

Still, according to the government target of vaccinating 40 million people by the end of this month, the country should have administered at least 70 million doses of vaccine by Thursday.

PS

Indonesia study finds China's Sinovac COVID-19 vaccine effective in medical staff

 

[阿土仔]

科兴说能在 10 weeks 内生产出针对变异病毒的疫苗​

Sinovac can produce updated COVID-19 vaccines against variants in 10 weeks
By
Wang Qi
Published: May 12, 2021 10:18 PM

Sinovac COVID-19 vaccine. Photo: VCG

Amid global concerns over the variant found in India that appears to be of high infectiousness and transmissibility, Chinese experts said Chinese vaccine manufacturers will be able to produce suitable vaccines against the variant in about two months.

The comment came as Chinese manufacturer Sinovac, whose COVID-19 vaccine is being used in more than 30 countries, disclosed to Ta Kung Pao newspaper that the company is studying different mutations and an updated vaccine suitable for these mutations could be produced in 10 weeks at the quickest after the company cultivates the mutated strain successfully.

Liu Peicheng, the spokesperson of Sinovac, told media on Tuesday in a Beijing-based manufacturing factory that the company is researching the different mutations of the novel coronavirus, a vital step before updated vaccines come into production.

With a mature vaccine pipeline in place, future production of COVID-19 vaccine will be much faster, Liu said, noting that Sinovac has been using its vaccine on a large scale in Brazil, Chile and in areas where it has found mutated strains, and has seen good protection against the virus.

Experts reached by Global Times said that Sinovac's claimed speed is not an exaggeration. After getting the mutant strain, manufacturers only need to replace the seed virus in the fermenter, without making any adjustment in other procedures.

The upgrade can be finished in two months, with an animal trial or a phase I human trial, and that's enough for emergency use, Tao Lina, a Shanghai-based vaccine expert, told the Global Times on Wednesday.

The original version of inactivated vaccine may offer slightly less protection against the virus with mutant strains, but a third dose of updated vaccine on top of the previous shots will provide much greater protection, Tao said.

Chinese experts said that insufficient evidence has been found to show that the B.1.617 variant found in India and classified by the WHO as "a variant of concern" could make current vaccines less effective. Experts noted that as the epidemic in India is still unstable and the mutation could continue to mutate, it is not a proper time to select and cultivate the strain for vaccines.

Yang Zhanqiu, deputy director of the pathogen biology department at Wuhan University, told the Global Times on Wednesday that deciding a strain of virus to produce an inactivated vaccine is a complex process, which usually is conducted at the end of an epidemic, to select the strain with the greatest impact.

But experts tried to ease public concern, saying that current vaccines are still able to provide protection against most mutations despite some reduction in efficacy. Vaccine research and development is still getting ahead of the virus mutation, they said.

They said that Sinovac's updated vaccine may elevate their status in the highly competitive international vaccine market with mRNA vaccines dominating the West as they can update the vaccines quicker due to mature technology, while more tests and research are needed to update mRNA vaccines as the technology has rarely been applied in the real world before the COVID-19 pandemic.

两个半月出针对变异的疫苗，那还等嘛？赶紧弄个对付印度3重变异的疫苗一展牛鼻！金票大大地有！

 

[向问天]

两个半月出针对变异的疫苗，那还等嘛？赶紧弄个对付印度3重变异的疫苗一展牛鼻！金票大大地有！

为印度研发疫苗？
想得美

 

[阿土仔]

为印度研发疫苗？
想得美

卖钱呀！笨！......

 

[superlover]

印尼要增加购买1亿剂科兴疫苗。

Redirect Notice

靠，我看成了印度，就给你点赞了

 

[lindamy]

靠，我看成了印度，就给你点赞了

要是印度就好了，现在世界太平一大半。

 

[woow]

还买？还卖？ 不长点心啊